Literature DB >> 19190032

The role of impaired mitochondrial lipid oxidation in obesity.

Mary Madeline Rogge1.   

Abstract

Obesity represents a disruption in balancing fuel intake with energy expenditure in favor of energy conservation. Adiposity is known to be carefully regulated and, over time, highly resistant to major changes, raising questions about how energy homeostasis can become dysregulated in favor of fat accumulation. In obesity, the excess lipid accumulation represents a surfeit of energy, but those who are obese often experience rapid fatigue and decreased physical endurance, reflecting an energy deficiency. To develop an explanation for this apparent contradiction in energy homeostasis and the chronic overeating relative to energy used in obesity, a review of the literature was conducted. The resulting model of obesity is based on a growing body of research demonstrating that altered mitochondrial energy production, particularly in skeletal muscles, is a major anomaly capable of setting off a chain of metabolic events leading to obesity. Alterations in skeletal muscle mitochondria distribution and their oxidative and glycolytic energy capacities in obesity are described. The metabolic responses of obese and normal individuals to exercise are contrasted, and the effects of weight loss on energy production are presented. The effect of altered fat oxidation is considered in relation to energy regulation by the central nervous system and the development of major obesity comorbidities, including systemic inflammation, insulin resistance and diabetes, and cardiovascular disease. Recommendations for clinical intervention and additional research are proposed based on the model presented of impaired mitochondrial function in obesity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19190032     DOI: 10.1177/1099800408329408

Source DB:  PubMed          Journal:  Biol Res Nurs        ISSN: 1099-8004            Impact factor:   2.522


  39 in total

Review 1.  Oxidative stress and inflammation interactions in human obesity.

Authors:  Isabel Bondia-Pons; Lisa Ryan; J Alfredo Martinez
Journal:  J Physiol Biochem       Date:  2012-02-17       Impact factor: 4.158

2.  Deacetylation by SIRT1 Reprograms Inflammation and Cancer.

Authors:  Tie Fu Liu; Charles E McCall
Journal:  Genes Cancer       Date:  2013-03

Review 3.  Mitochondria as a target in treatment.

Authors:  Marie-Céline Frantz; Peter Wipf
Journal:  Environ Mol Mutagen       Date:  2010-06       Impact factor: 3.216

Review 4.  Emerging Targets for Therapeutic Development in Diabetes and Its Complications: The RAGE Signaling Pathway.

Authors:  Ems Litwinoff; C Hurtado Del Pozo; R Ramasamy; A M Schmidt
Journal:  Clin Pharmacol Ther       Date:  2015-06-25       Impact factor: 6.875

5.  Reduced respiratory capacity in muscle mitochondria of obese subjects.

Authors:  Linda Bakkman; Maria Fernström; Peter Loogna; Olav Rooyackers; Lena Brandt; Ylva Trolle Lagerros
Journal:  Obes Facts       Date:  2010-09-17       Impact factor: 3.942

Review 6.  Angiotensin inhibition and longevity: a question of hydration.

Authors:  Simon N Thornton
Journal:  Pflugers Arch       Date:  2010-12-17       Impact factor: 3.657

7.  Obesity modifies the stoichiometry of mitochondrial proteins in a way that is distinct to the subcellular localization of the mitochondria in skeletal muscle.

Authors:  Katon A Kras; Paul R Langlais; Nyssa Hoffman; Lori R Roust; Tonya R Benjamin; Elena A De Filippis; Valentin Dinu; Christos S Katsanos
Journal:  Metabolism       Date:  2018-09-22       Impact factor: 8.694

8.  Mitochondrial ATP synthase β-subunit production rate and ATP synthase specific activity are reduced in skeletal muscle of humans with obesity.

Authors:  Lee Tran; Paul R Langlais; Nyssa Hoffman; Lori Roust; Christos S Katsanos
Journal:  Exp Physiol       Date:  2018-11-12       Impact factor: 2.969

9.  Effects of obesity and weight loss on mitochondrial structure and function and implications for colorectal cancer risk.

Authors:  S P Breininger; F C Malcomson; S Afshar; D M Turnbull; L Greaves; J C Mathers
Journal:  Proc Nutr Soc       Date:  2019-03-22       Impact factor: 6.297

10.  Ascorbic acid inhibits visceral obesity and nonalcoholic fatty liver disease by activating peroxisome proliferator-activated receptor α in high-fat-diet-fed C57BL/6J mice.

Authors:  Hyunghee Lee; Jiwon Ahn; Soon Shik Shin; Michung Yoon
Journal:  Int J Obes (Lond)       Date:  2018-10-03       Impact factor: 5.095

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.